Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges

References

• Bamford RN, Grant AJ, Burton JD, et al. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A. 1994;91:4940–4944.
   PubMed Web of Science ®Google Scholar
• Burton JD, Bamford RN, Peters C, et al. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A. 1994;91:4935–4939.
   PubMed Web of Science ®Google Scholar
• Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994;264:965–968.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6:595–601.
   PubMed Web of Science ®Google Scholar
• Guo Y, Luan L, Patil NK, et al. Immunobiology of the IL-15/IL-15Ra complex as an antitumor and antiviral agent. Cytokine Growth Factor Rev. 2017;38:10–21.
   PubMed Web of Science ®Google Scholar
• Tagaya Y, Bamford RN, DeFilippis AP, et al. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity. 1996;4:329–336.
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14–32.
   PubMed Web of Science ®Google Scholar
• Schluns KS, Lefrançois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 2003;3:269–279.
   PubMed Web of Science ®Google Scholar
• Budagian V, Bulanova E, Paus R, et al. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 2006;17:259–280.
   PubMed Web of Science ®Google Scholar
• Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by ?c family cytokines. Nat Rev Immunol. 2009;9:480–490.
   PubMed Web of Science ®Google Scholar
• Jabri B, Abadie V. IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction. Nat Rev Immunol. 2015;15:771–783.
   PubMed Web of Science ®Google Scholar
• Dubois S, Mariner J, Waldmann TA, et al. IL-15Ra recycles and presents IL-15 in trans to neighboring cells. Immunity. 2002;17:537–547.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Gavin MA, et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6:1142–1151.
   PubMed Web of Science ®Google Scholar
• D’Cruz LM, Klein L. Development and function of agonist-induced CD25+ Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol. 2005;6:1152–1159.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Pötschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14. 18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1617–1629.
   PubMed Web of Science ®Google Scholar
• Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol. 2005;86:209–239.
   PubMed Web of Science ®Google Scholar
• Vyas VV, Esposito D, Sumpter TL, et al. Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization. Biotechnol Prog. 2012;28:497–507.
   PubMed Web of Science ®Google Scholar
• Conlon KC, Lugli E, Welles HC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015;33:74–82.
   PubMed Web of Science ®Google Scholar
• Miller JS, Morishima C, McNeel DG, et al. A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors. Clin Cancer Res. 2018 Apr 1;24(7):1525–1535.
   PubMed Web of Science ®Google Scholar
• Conlon KC, Potter EL, Pittaluga S, et al. IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK cell subset expansion. Clin Cancer Res. 2019;25:4945–4954.
   PubMed Web of Science ®Google Scholar
• Casu B, Dondero A, Regis S, et al. Novel immunoregulatory functions of IL-18, an accomplice of TGF-ß1. Cancers (Basel). 2019;11:pii: E75.
   PubMed Web of Science ®Google Scholar
• Fujii R, Jochems C, Tritsch SR, et al. An IL-15 superagonist/IL-15Ra fusion complex protects and rescues NK cell-cytotoxic function from TGF-ß1-mediated immunosuppression. Cancer Immunol Immunother. 2018;67:675–689.
   PubMed Web of Science ®Google Scholar
• Romee R, Cooley S, Berrien-Elliott MM, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood. 2018;131:2515–2527.
   PubMed Web of Science ®Google Scholar
• Margolin K, Morishima C, Velcheti V, et al. Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors. Clin Cancer Res. 2018;24:5552–5561.
   PubMed Web of Science ®Google Scholar
• Wrangle JM, Velcheti V, Patel MR, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19:694–704.
   PubMed Web of Science ®Google Scholar
• Dimatteo R, Darling NJ, Segura T. In situ forming injectable hydrogels for drug delivery and wound repair. Adv Drug Deliv Rev. 2018;127:167–184.
   PubMed Web of Science ®Google Scholar
• Bergamaschi C, Kulkarni V, Rosati M, et al. Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells. Gene Ther. 2015;22:76–86.
   PubMed Web of Science ®Google Scholar
• Delconte RB, Kolesnik TB, Dagley LF, et al. CIS is a potent checkpoint in NK cell–mediated tumor immunity. Nat Immunol. 2016;17:816–824.
   PubMed Web of Science ®Google Scholar
• Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16:7–19.
   PubMed Web of Science ®Google Scholar
• Chiossone L, Dumas PY, Vienne M, et al. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18:671–688.
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Miljkovic MD, Conlon KC. Interleukin-15 (dys) regulation of lymphoid homeostasis: implications for therapy of autoimmunity and cancer. J Exp Med. 2020;217(1):pii: e20191062.
   PubMed Web of Science ®Google Scholar
• Janakiram M, Shah UA, Liu W, et al. The third group of the B7-CD28 immune checkpoint family: HHLA 2, TMIGD 2, B7x, and B7-H3. Immunol Rev. 2017;276:26–39.
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Kanegane H, Sgadari C, et al. Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun. 1997;233:231–237.
   PubMed Web of Science ®Google Scholar